MICA gene and relevance to immune responses in organ transplants and inflammatory, tumoral and autoimmune diseases

Current Immunology Reviews

Volumn 5, Issue 2, 2009, Pages 122-134

  Muro, Manuel ^a   López Hern acadez, Ruth ^a   Campillo, José Antonio ^a   Lucas, Daniel ^a   Martínez García, Pedro ^a   Botella, Carmen ^a   Minguela, Alfredo ^a   Álvarez López, Maria Rocío ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

MICA; Natural killer (NK); NKG2D; Polymorphism; Transplant; Tumors

Indexed keywords

ALPHA INTERFERON; ATM PROTEIN; ATR PROTEIN; CD94 ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE LCK; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DNA POLYMORPHISM; DOWN REGULATION; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENE LOCUS; GENE MAPPING; GENE TARGETING; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KAPOSI SARCOMA; LIGAND BINDING; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; UPREGULATION; VIRUS INFECTION;

EID: 68549130926     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339509788166967     Document Type: Review

References (162)

1. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994; 91: 6259-63.
2. Grubic Z, Stingl K, Zunec R, Car H, Cecuk-Jelicic E, Brkljacic-Kerhin V. Linkage disequilibria between human leucocyte antigen-B and closely linked microsatellites in the Croatian population. Tissue Antigens 2006; 69: 86-94.
3. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 1999; 10: 577-584.
4. Bahram S, Spies T. The MIC gene family. Res Immunol 1996; 147: 328-33.
5. Zwirner NW, Fernandez-Viña MA, Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998; 47: 139-48.
6. Zwirner NW, Fuertes MB, Girart MV, Doamica CI, Rossi LE. Immunobiology of the human MHC class I Chaín-related gene A (MICA): from transplantation immunology to tumor immune escape. Inmunologia 2006; 25: 25-38.
7. Steinle A, Groh V, Spies T. Diversification, expression, and gamma delta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules. Proc Natl Acad Sci USA 1998; 95: 12510-5.
8. Kasahara M, Watanabe Y, Sumasu M, Nagata T. A family of MHC class I-like genes located in the vicinity of the mouse leukocyte receptor complex. Proc Natl Acad Sci USA 2002; 99: 13687-92.
9. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocomaptibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-50.
10. Zou Y, Stastny P. Alternatively spliced forms of MICA and MICB lacking exon 3 in a human cell line and evidence of presence of similar RNA in human peripheral blood mononuclear cells. Immunogenetics 2002; 54: 671-4.
11. Gonzalez S, Martinez-Borra J, Torre Alonso JC, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic athritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999; 42: 1010.
12. Suemizu H, Radosavljevic M, Kimura M, et al. A basolateral sorting motif in the MICA cytoplasmic tail. Proc Natl Acad Sci USA 2002; 99: 2971-6.
13. Eagle RA, Taherne JA, Ashiru O, Wills MR, Trowsdale J. Regulation of NKG2D ligand gene expression. Hum Immunol 2006; 67: 159-169.
14. Marin ML, Savioli CR, Yamamoto JH, Kalil J, Goldberg AC. MICA polymorphism in a sample of the Sao Paulo population, Brazil. In: Immunobiology of the Human MHC. Vol II. Hansen JA (eds.). PJ Schmidt Grafisk, Vojens, Denmark. 2006. 476-9.
15. Muñoz-Saa I, Cambra A, Pallares L, et al. Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behcet's disease. Scand J Immunol 2006; 64: 77-82.
16. Albert E, Yao Z, Chandanayingyong D, et al. Anthropology/human genetic diversity population reports. MICA report. In: Hansen JA, Dupont B (eds): HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress. Seatle, WA, IHWG Press, 2004.
17. Petersdorf EW, Shuler KB, Longron GM, Spies T, Hansen JA. Population study of allelic diversity in the human MHC class I-related MIC-A gene. Immunogenetics 1999; 49: 605-12.
18. Gonzalez S, Brautbar C, Martinez-Borm J, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 2001; 62: 632-8.
19. Zhang Y, Han M, Vorhaben R, Giang C, Lavingia B, Stastny P. Study of MICA alleles in 201 African Americans by multiplexed single nucleotide extension (MSNE) typing. Hum Immunol 2003; 64: 130.
20. Collins RWM. Human MHC class I chain related (MIC) genes: their biological function and relevance to disease and transplantation. Eur J Immunogenet 2004; 31: 105-14.
21. Hughes EH, Collins RWM, Kondeatis E, et al. Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients. Tissue Antigens 2005; 66: 195-9.
22. Zou Y, Han M, Wang Z, Stasny P. MICA allele-level typing by sequence-based typing with computerized assignment of polymorphic sites and short tanderp repeats within the transmembrane region. Hum Immunol 2006; 67: 145-51.
23. Lucas D, Campillo JA, López-Hernández R, et al. Allelic Diversity of MICA Gene and MICA/HLA-B Haplotypic Variation in the Murcia Region Population (South-Eastern Spain). In press.
24. Piancatelli D, Del Beato T, Oumhani K, El Aouad R, Adorno D. MICA polymorphism in a population from North Morocco, Metalsa Berbers, using sequence-based typing. Hum Immunol 2005; 66: 931-6.
25. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
26. Zhang Y, Stastny P. MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity. Hum Immunol 2006; 67: 215-22.
27. Romphruk AV, Romphruk A Choonhakam C, Puapairoj C, Inoko H, Leelayuwat C. Major histocompatibility complex class I chain-related gene A in Thai psoriasis patients: MICA association as a part of human leukocyte antigen-B-Cw haplorypes. Tissue Antigens 2004; 63: 547-54.
28. Komatsu-Wakui M, Tokunaga K, Ishikawa Y, et al. Wide distribution of the MICA-MICB null haplotype in East Asians. Tissue Antigens 2001; 57: 1.
29. Tian W, Boggs DA, Uko G, et al. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes Immunity 2003; 4: 500-5.
30. Gong W, Yang J, Yao F, X Lingdi, Fan L. Analysis on polymorphism in exons 2, 3 and 4 of the MICA gene in three different Chinese populations. In: Immunobiology of the Human MHC. Vol II. Hansen JA (eds). PJ Schmidt Grafisk, Vojens, Denmark. 2006. 470-2.
31. Bolognesi E, D'Alfonso S, Rolando V, Fasano ME, Practico L, Momigliano-Richiardi P. MICA and MICB microsatellite alleles in HLA extended haplotypes. Eur J Immunogenet 2001; 28: 523.
32. Zhang Y, Lazaro AM, Zou Y, Lavingia B, Moraes EM, Moraes RJ, Stasmy P. MICA polymorphism. in South American Indians. Immunogenetics 2002; 53: 900.
33. Pyo CW, Hur SS, Kim YK, Choi HB, Kin TY, Kim TG. Distribution of MICA alleles and haplotypes associated with HLA in the Korean population. Hum Immunol 2003; 64; 378.
34. Gao X, Single RM, Karacki P, Marti D, O'Brien SJ, Carrington M. Diversity of MICA and linkage disequilibrim with HLA-B in two North American populations. Hum Immunol 2006; 67: 152-158.
35. Molinero LL, Marcos CY, Mirbaha F, Fainboim L, Stastny P, Zwirner NW. Codominant expresión of the polymorphic MICA alloantigens encoded by genes in the HLA region. Eur J Immunogenet 2002; 29: 315-9.
36. Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999; 60: 323-30.
37. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-40.
38. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-86.
39. Hue S, Monteiro RC, Berrich-Aknin S, Caillat-Zucman S. Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 cells. J Immunol 2003: 171: 1909-17.
40. Molinero LL, Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW. Activation-induced expresión of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol 2002; 71: 791-7.
41. Molinero LL, Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW. Up-regulated expresión of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol 2003; 73: 815-22.
42. Molinero LL, Fuertes MB, Girart MV, Fainboim L, Rabinovich GA, Costas MA, Zwirner NW. NF-kB regulates expresión of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol 2004; 173: 5583-90.
43. Jinushi M, Takehara T, Kanto T, et al. Critical role of MHC class I-related chain A and B expression on IFN-α stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003; 170: 1249-56.
44. Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/paracrine IL-15 that is required for type 1 IFN-mediated dendritic cells expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 2003; 171: 5423-9.
45. Dann SM, Wang HC, Cambarin KJ, et al. Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis 2005; 192; 1294-302.
46. Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue micro-environment. J Immunol 2001; 167: 5527-30.
47. Zhang C, Niu J, Zhang J, et al. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci 2008; 99: 1279-86.
48. Gannage M, Buzyn A, Bogiatzi SI, Lambert M, Soumelis V, Dal Cortivo L. Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host-disease. Transplantation 2008; 27: 911-5.
49. McCann FE, Eissmann P, Önfelt B, Leung R, Davis DM. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol 2007; 178: 3418-26.
50. Tieng V, Le Bouguenec C, du Merle L, et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 2002; 99: 2977-82.
51. Ostberg JR, Dayanc BE, Yuan M, Oflazoglu E, Repasky EA. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 2007; 82: 1322-31.
52. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90.
53. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?. Curr Opin Immunol 2002; 14: 306-11.
54. Strid J, Roberts SJ, Filler RB, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol 2008; 9: 146-54.
55. Mincheva-Nilson L, Nagaeva O, Chen T, et al. Placenta derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 2006; 3585-92.
56. Porcu-Buisson G, Lambert M, Lyonnet L, et al. Soluble MHC class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. Hum Reprod 2007; 22: 2261-6.
57. Bauer S, Groh V, Wu J, Steinle a, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
58. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related related chains by human epithelial gamma delta T cells. J Immunol 2002; 169: 1236-40.
59. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-2.
60. Andre P, Castriconi R, Espeli M, et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004; 34: 961-71.
61. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4: 557-64.
62. Scrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. Plos One 2007; 6: e518.
63. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001; 2: 443-51.
64. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligand MICA, MICB and homologs of the mouse RAE-1 protein family. Immunogenetics 2001; 53: 279-87.
65. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-33.
66. Chalupny JN, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 2003; 305: 129-35.
67. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002; 169: 4079-83.
68. Strong RK. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. Mol Immunol 2001; 38: 1029-37.
69. Groh V, Rhinehart R, Randolph-Habecker J, Topps MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagements by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-60.
70. Girart MV, Fuertes MB, Doamica CI, Rossi LE, Zwirner NW. Engagement of TLR3, TLR7, and NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 2007; 179: 3472-79.
71. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 2007; 110: 606-15.
72. Wrobel P, Shojaei H, Schittek B, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition.. Scand J Immunol 2007; 66: 320-28.
73. Friese MA, Platten M, Lutz S, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63: 8996-9006.
74. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-b enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenity in vivo. Cancer Res 2004; 64: 7596-603.
75. Menier C, Riteau B, Carosella ED, Rouas-Freiss N. MICA triggering signal for NK cells tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 2002; 100: 63-70.
76. Vetter CS, Groh V, thor Straten P, Spies T, Brocker EB, Becker JC. Expression of stress-induced MHC class I related chain molecules on human melanomas. J Invest Dermatol 2002; 118: 600-5.
77. Vetter CS, Lieb W, Brocker EB, Becker JC. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 2004; 91: 1495-9.
78. Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891-9.
79. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxity. Cancer Res 2002; 62: 6178-86.
80. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105: 1285-90.
81. Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003; 33: 2033-43.
82. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102; 1389-96.
83. Wagsater D, Dimberg J, Hugander A, Sirsjo A, Ghaderi M. Analysis of MICA gene transcript in human rectal cancers. Anticancer Res 2003; 23: 2525-29.
84. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251-8.
85. Romanski A, Bug G, Becker S, et al. Mechanism of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005; 33: 344-52.
86. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-7.
87. Reinders J, Rozemuller EH, van der Ven KJW, et al. MHC class I chain-related gene A diversity in head and neck squamous cell carcinoma. Hum Immunol 2005; 67: 196-203.
88. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG. Human leucocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin Cancer Res 2008; 14: 2028-35.
89. Lu S, Xiao P, Xue L, et al. Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma. Neoplasma 2008; 55: 266-72.
90. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NFS, Ellis I, Durrant LG. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immunity 2007; 7: 17-26.
91. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106: 1711-7.
92. Girlanda S, Fortis C, Belloni D, et al. MICA expressed by multiple myeloma and monoclonal gammapathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 2005; 65: 7502-8.
93. Watson NF, Spendlove I, Madjd Z, et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 2005; 118: 1445-52.
94. Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD, Zhang DL. NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand J Immunol 2008; 67: 441-7.
95. Wiemann K, Mittrucker HW, Feger U, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175: 720-9.
96. Bahram S, Inoko H, Shiina T, Radosavljevic M. MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol 2005; 17: 505-9.
97. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6: 928-37.
98. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-7.
99. Molinero LL, Damaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006; 67: 170-82.
100. Arreygue-Garcia N, Daneri-Navarro A, del Toro-Arreola A, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008; 8: 16.
101. Fuertes MB, Girart MV, Molinero LL, et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK-cell-mediated cytotoxicity. J Immunol 2008; 180: 4606-14.
102. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004; 49: 179-86.
103. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-21.
104. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
105. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enables shedding of tumor associated NKG2D ligands. Nature 2007; 447: 482-7.
106. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40.
107. Glick AB. TGF-β1, back to the future. Revisiting its role as a transforming growth factor. Cancer Biol Ther 2004; 3: 276-83.
108. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100: 2281-91.
109. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-51.
110. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97-113.
111. Poggi A, Massaro AM, Negrini S, Contini P, Zocchi MR. Tumor-induced apoptosis of human IL-2 activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005; 174: 2653-60.
112. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180: 7249-58.
113. Elsner L, Muppala V, Gehrmann M, et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007; 179: 5523-33.
114. Takaki R, Hayakawa Y, Nelson A, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 2005; 175: 2167-73.
115. Busche A, Goldmann T, Naumann U, Steinle A, Brandau S. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene a. Hum Gene Ther 2006; 17: 135-46.
116. Kato N, Tanaka J, Sugita J, et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007; 21: 2103-8.
117. Tang B, Yang Z, Huang J, et al. Evaluation of human major histocompatibility complex class I chain-related A as a potential target for human tumor imaging. Cancer Lett 2008; 263: 99-106.
118. Muro M, Sánchez-Bueno F, Marín L, et al. Relationship between CDC crossmatch in liver recipients and antibodies screening by flow cytometry. Transplant Proc 2003; 35: 1894-5.
119. Muro M, Marin L, Miras M, et al. Human liver allograft recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor graft survival at the first year after transplantation. Experience of one centre. Transplant Immunol 2005; 14: 91-7.
120. Muro M, Llorente S, Marín L, et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRA™, ELISA and CDC vs luminex screening. Nephr Dyal Transplant 2005; 20: 223-6.
121. Muro M, Palacios S, Moya-Quiles MR, Candela M, Álvarez-López MR. Acute haemolytic transfusion reaction secondary to HLA alloimmunization. Int Jnl Lab Haematol 2008; 30: 84-6.
122. Muro M, Rivera J, Botella C, Campillo JA, Ferrer F, Álvarez-López MR. HLA-DR antibodies in Transfusion-Related Acute Lung Injury (TRALI): A case report. Transfusion Apheresis Science 2008; 38: 209-12.
123. Mizutani K, Terasaki PI, Shih RMJ, Pei R, Ozawa M, Lee J. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol 2006; 67: 223-229.
124. Suarez-Alvarez B, López-Vazquez A, González MZ, et al. The relationship of Anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007; 7: 1842-8.
125. Stastny P. Introduction: MICA/MICB in innate immunity, adaptative immunity, autoimmunity, cancer, and in the immune response to transplants. Hum Immunol 2006; 67: 141-4.
126. Ozawa M, Terasaki PI, Lee JH, et al. 14th International HLA and immunogenetics workshop: report on the prospective chronic rejection project. Tissue Antigens 2007; 69 (Suppl 1): 174-9.
127. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357; 1293-300.
128. Panigrahi A, Gupta N, Siddiqui JA, et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 2007; 68: 362-7.
129. Hankey KG, Drachenberg CB, Papadimitriu JC, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002; 73: 304-6.
130. Rauen U, de Grofft H. New insights into the cellular and molecular mechanism of cold storage injury. J Investig Med 2004; 52: 299-309.
131. Kitcharoen K, Witt CS, Romphruk AV, Christiansen FT, Leelayuwat C. MICA, MICB, and MHC beta block matching in bone marrow transplantation. Hum Immunol 2006; 67: 238-46.
132. Martínez A, Fernández-Arquero M, Balsa A, et al. Primary association of a MICA allele with protection against rheumatoid arthritis. Arthritis Rheum 2001; 1261-5.
133. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity?. Hum Immunol 2005; 67: 204-7.
134. Molinero LL, Gruber M, Leoni J, Woscoff A, Zwirner NW. Upregulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol 2003; 106: 50-4.
135. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its ligands in rheumatoid arthritis. Proc Natl Acad Sci 2003; 100: 9452-7.
136. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/ MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367-77.
137. Mention JJ, Ben Ahmed M, Beguebegue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125: 730-45.
138. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL-15 of a TCR-independent NKG2D signaling pathways converts CTL into lymphokine-activated killer cell in celiac disease. Immunity 2004; 21; 357-66.
139. López-Vázquez A, Rodrigo L, Fuentes D, et al. MHC class I Caín related gene A (MICA) modulates the development of coeliac disease in patients with the high risk heterodimer DQA1*0501/DQB1 *0201. Gut 2002; 50: 336-40.
140. Tinto N, Ciacci C, Calcagno G, et al. Increased prevalence of celiac disease without gastrointestinal symptoms in adults MICA 5.1 homozygous subjects from the Campania area. Dig Liver Dis 2008; 40: 248-52.
141. Glas J, Martin K, Brünnler G, Kopp R, Folwaczny C, Weiss EH, Albert ED. MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. Tissue Antigens 2001; 58: 243-9.
142. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007; 132: 2346-58.
143. Orchard TR, Dhar A, Simmons D, Vaughan R, Welsh KI, Jewell DP. MHC class I chain-like gene A (MICA) and its association with inflammatory bowel disease and peripheral arthropathy. Clin Exp Immunol 2001; 126: 437-40.
144. Tay GK, Hui J, Gaudieri S, et al. PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphism are associated with psoriasis. Clin Exp Immunol 2000; 119: 553-8.
145. Gambelunghe G, Ghaderi M, Consentino A, et al. Association of MHC class I chain-related A (MIC-A) gene polymorphism with Type 1 diabetes. Diabetologia 2000; 43: 597.
146. Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J Clin Endocrinol Metab 1999; 84: 3701.
147. Gambelunghe G, Brozzetti A, Ghaderi M, Candeloro P, Tortoioli C, Falorni A. MICA gene polymorphism in the pathogenesis of type 1 diabetes. Ann N Y Acad Sci 2007; 1110: 92-8.
148. Field SF, Nejentsev S, Walker NM, et al. Sequencing-based genotyping and association analysis of the MICA and MICB genes in type 1 diabetes. Diabetes 2008; Marzo 10 [Epub ahead of print].
149. Alizadeh BZ, Eerligh P, van der Slik AR, et al. MICA marks additional risk factors for Type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. Mol Immunol 2007; 44: 2806-12.
150. Mizuki N, Meguro A, Tohnai I, Gül A, Ohno S, Mizuki N. Association of major histocompatibility complex class I chain-related A and HLA-B alleles with Behcet's disease in Turkey. Jpn J Ophthalmol 2007; 51: 431-6.
151. Holdenrieder S, ichhorn, Beuers U, et al. Soluble NKG2D ligands in hepatic autoimmune diseases ad in benign diseases involved in marker metabolism. Anticancer Res 2007; 27: 2041-45.
152. Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci 2007; 31; 1220-28.
153. Cerboni C, Neri F, Casartelli N, et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediqated cytotoxicity. J Gen Virol 2007; 88: 242-50.
154. Welte SA, Sinzger C, Lutz SZ, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003; 33: 194-203.
155. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D. Human cytomegalovirus glycoprotein IL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003; 197: 1427-39.
156. Zou Y, Bresnahan W, Taylor RT, Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 2005; 3098-104.
157. Huang BS, Luo QZ, Mei B, Yu P. Correlation between MHC class I-related chain A gene *008 allele and human cytomegalovirus infection. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 509-11.
158. Thomas M, Boname JM, Field S, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci USA 2008; 105: 1656-61.
159. McSharry BP, Burget HG, Owen DP, et al. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol 2008; 82: 4585-94.
160. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
161. Bravo MJ, Colmenero JD, Martin J, Alonso A, Caballero A. Polymorphism of the transmembrane region of the MICA gene and human brucellosis. Tissue Antigens 2007; 69: 358-60.
162. Zhang S, Hue S, Sene D, et al. Expression of major histocompatibility complex class I chain-related molecule A, NKG2D, and transforming growth factor-beta in the liver of humans alveolar echinococcosis: new actors in the tolerance to parasites? J Infect Dis 2008; 197: 1341-9.